This federal contract IDV, awarded by the U.S. Department of Veterans Affairs (VA), establishes a $5.5 billion multiple-award Federal Supply Schedule (FSS) contract with Gilead Sciences Inc. (doing business as Gilead) for the provision of pharmaceutical and drug products, primarily focused on antiviral treatments, cancer immunotherapies, and drugs for pulmonary hypertension.
Under this FSS contract, Gilead has received numerous firm-fixed-price delivery orders from various VA Integrated Service Networks to supply critical medications such as Veklury (remdesivir) for COVID-19 treatment, Yescarta and Tecartus for cancer immunotherapies, and Letairis for pulmonary arterial hypertension. Additionally, Gilead holds a $29.16 million single-award Blanket Purchase Agreement (BPA) with the VA National Acquisition Center for the procurement of Letairis, Yescarta, and Tecartus through October 2025, enabling efficient ordering of these specialty medications by VA facilities nationwide. These IDVs demonstrate Gilead's established role as a key supplier of life-saving pharmaceuticals to the federal government's healthcare programs.
Generated 1/4/25, 9:06 AM